Adial Pharmaceuticals Names Matt Davidson President and CEO

• Adial Pharmaceuticals appointed former Verrica Pharmaceuticals CEO Matt Davidson president and CEO, effective October 28, 2026.
• Julie Saiki became chief strategy officer; she previously led Stanford's Phase 1b ulcerative colitis study and consulted at McKinsey & Company.
• Celia Economides joined as chief financial officer, having most recently served as CellCentric's chief financial and business officer.
• David Rubenstein became chief scientist; he previously served as Dermavant Sciences' chief scientific officer, leading tapinarof development.
• Ajay Duggal was appointed consulting chief medical officer; he previously led Takeda's general medicine therapeutic area as vice president.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adial Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-113337), on October 28, 2026, and is solely responsible for the information contained therein.